ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02371408
Recruitment Status : Unknown
Verified October 2015 by Pharco Pharmaceuticals.
Recruitment status was:  Active, not recruiting
First Posted : February 25, 2015
Last Update Posted : April 7, 2016
Sponsor:
Information provided by (Responsible Party):
Pharco Pharmaceuticals

Brief Summary:

The study will assess the efficacy of PPI-668 (USAN: ravidasvir hydrochloride) in combination with sofosbuvir, with or without ribavirin, in the following Egyptian HCV gt-4 patient populations:

  1. Treatment-naïve patients, with and without cirrhosis (Group 1)
  2. Previous non-responders to interferon-based therapies, without cirrhosis (Group 2)
  3. Previous non-responders to interferon-based therapies, with cirrhosis (Group 3)

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Drug: ravidasvir hydrochloride Drug: sofosbuvir Drug: ribavirin Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
Study Start Date : January 2015
Actual Primary Completion Date : January 2016
Estimated Study Completion Date : April 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1a: Treatment-naive patients, without ribavirin (RBV)
PPI-668 + sofosbuvir for 12 weeks
Drug: ravidasvir hydrochloride
200 mg
Other Name: PPI-668

Drug: sofosbuvir
400 mg

Experimental: 1b: Treatment-naive patients, with RBV
PPI-668 + sofosbuvir + ribavirin (RBV) for 12 weeks
Drug: ravidasvir hydrochloride
200 mg
Other Name: PPI-668

Drug: sofosbuvir
400 mg

Drug: ribavirin
1000 mg - 1200 mg per day, weight-based dosing

Experimental: 2a: Non-cirrhotic previous non-responders, without RBV
PPI-668 + sofosbuvir for 12 weeks
Drug: ravidasvir hydrochloride
200 mg
Other Name: PPI-668

Drug: sofosbuvir
400 mg

Experimental: 2b: Non-cirrhotic previous non-responders, with RBV
PPI-668 + sofosbuvir + ribavirin for 12 weeks
Drug: ravidasvir hydrochloride
200 mg
Other Name: PPI-668

Drug: sofosbuvir
400 mg

Drug: ribavirin
1000 mg - 1200 mg per day, weight-based dosing

Experimental: 3a: Cirrhotic previous non-responders 12 weeks
PPI-668 + sofosbuvir + ribavirin for 12 weeks
Drug: ravidasvir hydrochloride
200 mg
Other Name: PPI-668

Drug: sofosbuvir
400 mg

Drug: ribavirin
1000 mg - 1200 mg per day, weight-based dosing

Experimental: 3b: Cirrhotic previous non-responders 16 weeks
PPI-668 + sofosbuvir + ribavirin for 16 weeks
Drug: ravidasvir hydrochloride
200 mg
Other Name: PPI-668

Drug: sofosbuvir
400 mg

Drug: ribavirin
1000 mg - 1200 mg per day, weight-based dosing




Primary Outcome Measures :
  1. Proportions of patients who achieve Sustained Virologic Response at 12 weeks post-treatment (SVR12) [ Time Frame: post-treatment week 12 ]
    Sustained Virologic Response is defined as serum HCV RNA < LLOQ at post-treatment visits.


Secondary Outcome Measures :
  1. Proportions of patients who achieve Sustained Virologic Response at 4 weeks post-treatment (SVR4) [ Time Frame: post-treatment week 4 ]
  2. Proportions of patients who achieve Sustained Virologic Response at 24 weeks post-treatment (SVR 24) [ Time Frame: post-treatment week 24 ]
  3. Proportion of treated study participants prematurely discontinuing study treatment for any reason, proportion prematurely discontinuing treatment for lack of efficacy or for clinical adverse events or laboratory abnormalities [ Time Frame: during treatment and up to 24 weeks post-treatment ]
  4. Proportion of patients experiencing treatment-emergent adverse events, and proportion of patients experiencing adverse events considered to be probably or possibly related to one or more of the study drugs [ Time Frame: during treatment and up to 24 weeks post-treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or females, ≥ 18 years & ≤ 65 years of age.
  2. HCV antibody positive, with serum HCV RNA ≥ 10,000 IU/mL, with clinical history compatible with chronic hepatitis C.
  3. HCV genotype-4 infection, confirmed at the central study laboratory
  4. Body mass index (BMI) between 18 and 35 kg/m2, inclusive.
  5. Both male and female patients who have childbearing potential must agree to practice an acceptable method of birth control during the study and for at least 6 months after the cessation of treatment; such contraceptive methods must include at least one barrier method.
  6. Patients for Group 1 must be treatment-naïve - i.e., they have never received any antiviral treatment for their HCV infection, including interferon, pegylated interferon, ribavirin, or other regulatory-approved or investigational HCV antiviral therapies.
  7. Patients for Groups 2 and 3 must have previously failed treatment with an interferon-based therapy - i.e., interferon or pegylated interferon, with or without ribavirin, with no other previous HCV antiviral therapies.

    Patients for Group 2 must be non-cirrhotic diagnosed on screening visit by both Fibroscan™ liver stiffness measurement < 12.5 kPa and FIB-4 score < 3.25 if the results of Fibroscan and FIB-4 score are not matching; liver biopsy will be used for detection of cirrhosis. In case that the liver biopsy is not applicable, hepatic imaging or ultrasound reports could be used for determination of cirrhosis.

    Patients for Group 3 must have underlying cirrhosis diagnosed on screening visit by both Fibroscan liver stiffness measurement > 12.5 kPa and FIB-4 score > 3.25, if the results of Fibroscan and FIB-4 score are not matching liver biopsy will be used for detection of cirrhosis. In case that the liver biopsy is not applicable, hepatic imaging or ultrasound reports could be used for determination of cirrhosis.

  8. Willing and able to give informed consent
  9. Willing and able to complete all study visits and procedures, including compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

  1. Mixed genotype or non-typable HCV genotype infection,
  2. Positive test for HBsAg or HIV antibody, or IgM antibody to HAV or HEV
  3. History of schistosomiasis or positive test for schistosoma surface antigen at Screen.
  4. Serum alpha-fetoprotein (AFP) >100ng/ml. Patients with an AFP between 50 and 100ng/ml may be included as long as a liver ultrasound within 3 months of Screening, or at Screening, shows no evidence of potential hepatocellular cancer.
  5. History of treatment with any investigational or regulatory-approved direct-acting antiviral (DAA) agent for HCV infection - nucleos(t)ide or non-nucleosidic HCV polymerase inhibitor, HCV protease inhibitor, NS5A inhibitor, or other antiviral agent for HCV infection other than pegylated -interferon and/or ribavirin Previous pegylated interferon and/or ribavirin treatment is allowed for Groups 2 and 3 but prohibited for group 1, as noted above in Inclusion criterion 6)
  6. Evidence of a medical condition other than HCV that is contributing to liver disease
  7. History of, or clinical signs of, hepatic decompensation or portal hypertension:

    Variceal bleeding, or documented esophageal or GI varices (at investigator discretion, patients suspected of having esophageal varices should be evaluated by endoscopy, and varices excluded) Ascites by history or on physical examination Documented or suspected hepatic encephalopathy

    Physical signs of portal hypertension:

    Clinically significant splenomegaly Spider angiomata History of porto-systemic shunt procedure(s)

  8. Uncontrolled diabetes mellitus as evidenced by HgbA1C ≥ 8.5% at Screening.
  9. Hemoglobin < 11g/dL for females and < 12 g/dL for males
  10. WBC count < 3,500/mm3 OR absolute neutrophil count (ANC) < 1800/mm
  11. Platelet count < 75,000/mm3
  12. Serum creatinine > 1.3 x ULN OR creatinine clearance (GFR) < 50 mL/minute
  13. Serum ALT or AST >10x ULN
  14. Serum albumin ≤ 3.2 g/dl
  15. Direct serum bilirubin > 2xULN
  16. INR > 1.7.
  17. History of poorly controlled asthma, with one or more hospitalizations or emergency room visits in the previous 6 months
  18. History of any malignancy within the last 5 years (except prostate cancer still within Glisson's capsule or basal cell carcinoma of the skin).
  19. History of alcohol abuse as assessed by the investigator within the past 2 years, or an alcohol use pattern that may interfere with the patient's study compliance. Patients must have abstained from alcohol for at least 6 months prior to study start.
  20. History of drug abuse as assessed by the investigator within the last 2 years.
  21. Pregnancy, including current lactation in female patients, male patients with partners who are pregnant, or female patients intending to become pregnant.
  22. Major surgery requiring overnight hospitalization within 3 months prior to Screening
  23. Participation in another clinical trial of an investigational drug or device within 6 months prior to Screening
  24. Current use or history of use within the preceding 6 months of immunosuppressive or immune-modulating agents, including: azathioprine, systemic corticosteroids (prednisone or prednisone equivalent of more than 10mg/day for more than 10 days), or other immunosuppressive agents. Use of inhaled steroids for mild/moderate asthma and topical steroids for minor skin conditions is allowed.
  25. History of solid organ or bone marrow transplantation.
  26. History of use of medications associated with QT prolongation concurrently or within the 30 days prior to Screening Visit, including: macrolides, antiarrhythmic agents, azoles, fluoroquinolones, and tricyclic anti-depressants.
  27. correction, or a personal or family history of Torsades de Pointe.
  28. Cardiac ischemia with history of recurrent angina, clinically symptomatic cardiac abnormalities, or requirement for cardiac pacemaker
  29. History of a known allergy to ribavirin (RBV), or any excipient in the investigational product, or history of drug or other allergy that, in the opinion of the investigator, mitigates against study participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02371408


Locations
Egypt
Al-Qahira Al-Fatimeya MoH Hospital
Cairo, Egypt
Kasr El Aini Viral Hepatitis Center
Cairo, Egypt
National Liver Institute
Menoufiya, Egypt
Sponsors and Collaborators
Pharco Pharmaceuticals
Investigators
Principal Investigator: Gamal Esmat, M.D. Kasr El Aini Viral Hepatitis Center

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pharco Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02371408     History of Changes
Other Study ID Numbers: PPI-668-202
First Posted: February 25, 2015    Key Record Dates
Last Update Posted: April 7, 2016
Last Verified: October 2015

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Ribavirin
Sofosbuvir
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents